Advertisement Pharmaceutical Business review - Page 119 of 5294 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 16, 2026

Transcripta Bio, Mayo Clinic join force on ALS therapies

Transcripta Bio has entered into a research collaboration and licensing agreement with Mayo Clinic to identify potential treatments and therapeutic targets for amyotrophic lateral sclerosis (ALS).

The work aims to elucidate how ALS biology varies across patients and accelerate the development of targeted therapies. Credit: Faizal Ramli/Shutterstock.com.